KRAS and myeloproliferative disorder: In these models, whereas loss of ICMT was able to ameliorate KRAS-driven myeloproliferative disease (Wahlstrom et al, 2008), loss of ICMT accelerated disease progression of KRAS-driven pancreatic neoplasia (Court et al, 2013).